International Scholarly Research Notices / 2011 / Article / Tab 2

Review Article

Molecular Diagnosis of Sexually Transmitted Chlamydia trachomatis in the United States

Table 2

Performance characteristics of three commercially-available Chlamydia trachomatis molecular screening platforms per manufacturer-provided data. Ranges reflect differences in performance characteristics between specimens collected from symptomatic and asymptomatic individuals (when specified).

Commercial assayGenderSpecimenPerformance indices
Sensitivity range (%)Specificity range (%)

AMPLICORFemaleEndocervical87.4–94.098.6
Urine84.3–89.598.0–98.8
MaleUrethral96.3–98.795.2–97.7
Urine87.6–92.091.9–95.7

BD ProbeTec ETFemaleEndocervical88.7–96.897.9–98.5
Urine77.0–83.998.2–98.3
MaleUrethral89.5–95.592.9–97.0
Urine89.5–95.489.4–95.8

APTIMA Combo 2FemaleEndocervical92.4–98.496.7–98.8
Urine93.8–96.898.8–99.0
MaleUrethral94.6–96.496.9–98.4
Urine96.3–98.598.4–98.8

APTIMA Combo 2 clinician-collected vaginal swab sensitivity range 96.5–96.7%, specificity range 96.4–97.2%; APTIMA Combo 2 patient-collected vaginal swab sensitivity 98.4%, specificity 96.8%.